These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 7752146

  • 1. Significance of the levels of carboxy terminal type II procollagen peptide, chondroitin sulfate isomers, tissue inhibitor of metalloproteinases, and metalloproteinases in osteoarthritis joint fluid.
    Shinmei M, Kobayashi T, Yoshihara Y, Samura A.
    J Rheumatol Suppl; 1995 Feb; 43():78-81. PubMed ID: 7752146
    [Abstract] [Full Text] [Related]

  • 2. Procollagen II C-propeptide in joint fluid: changes in concentration with age, time after knee injury, and osteoarthritis.
    Lohmander LS, Yoshihara Y, Roos H, Kobayashi T, Yamada H, Shinmei M.
    J Rheumatol; 1996 Oct; 23(10):1765-9. PubMed ID: 8895155
    [Abstract] [Full Text] [Related]

  • 3. Temporal patterns of stromelysin-1, tissue inhibitor, and proteoglycan fragments in human knee joint fluid after injury to the cruciate ligament or meniscus.
    Lohmander LS, Roos H, Dahlberg L, Hoerrner LA, Lark MW.
    J Orthop Res; 1994 Jan; 12(1):21-8. PubMed ID: 8113939
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis.
    Ishiguro N, Ito T, Ito H, Iwata H, Jugessur H, Ionescu M, Poole AR.
    Arthritis Rheum; 1999 Jan; 42(1):129-36. PubMed ID: 9920023
    [Abstract] [Full Text] [Related]

  • 6. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis.
    Martel-Pelletier J, McCollum R, Fujimoto N, Obata K, Cloutier JM, Pelletier JP.
    Lab Invest; 1994 Jun; 70(6):807-15. PubMed ID: 8015285
    [Abstract] [Full Text] [Related]

  • 7. Synovial fluid cartilage metabolism marker concentrations in osteonecrosis of the femoral head compared with osteoarthrosis of the hip.
    Iwase T, Hasegawa Y, Ishiguro N, Ito T, Iwasada S, Kitamura S, Iwata H.
    J Rheumatol; 1998 Mar; 25(3):527-31. PubMed ID: 9517775
    [Abstract] [Full Text] [Related]

  • 8. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis.
    Manicourt DH, Poilvache P, Van Egeren A, Devogelaer JP, Lenz ME, Thonar EJ.
    Arthritis Rheum; 2000 Feb; 43(2):281-8. PubMed ID: 10693867
    [Abstract] [Full Text] [Related]

  • 9. [Clinical usefulness of the measurement of type-II procollagen carboxypeptide (C-II propeptide, pColl-II-C) in synovial fluid as a marker of collagen metabolism in cartilage].
    Shinmei M, Nagaya I, Miyanaga Y, Iwata H, Yamamoto S, Torisu T, Fujii K, Fukubayashi T, Kondo M, Kurosaka M.
    Ryumachi; 1992 Oct; 32(5):453-60. PubMed ID: 1440081
    [Abstract] [Full Text] [Related]

  • 10. MMP proteolysis of the human extracellular matrix protein aggrecan is mainly a process of normal turnover.
    Struglics A, Hansson M.
    Biochem J; 2012 Sep 01; 446(2):213-23. PubMed ID: 22670872
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis.
    Kanyama M, Kuboki T, Kojima S, Fujisawa T, Hattori T, Takigawa M, Yamashita A.
    J Orofac Pain; 2000 Sep 01; 14(1):20-30. PubMed ID: 11203734
    [Abstract] [Full Text] [Related]

  • 14. Fibronectin fragments in osteoarthritic synovial fluid.
    Xie DL, Meyers R, Homandberg GA.
    J Rheumatol; 1992 Sep 01; 19(9):1448-52. PubMed ID: 1433014
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Levels of matrix metalloproteinase-3 and urokinase-type plasminogen activator in knee synovial fluids from patients with rheumatoid arthritis and osteoarthritis].
    Gotoh H, Yamada H, Yoshihara Y, Kikuchi T, Obata K, Shinmei M.
    Ryumachi; 1997 Feb 01; 37(1):3-8. PubMed ID: 9128417
    [Abstract] [Full Text] [Related]

  • 17. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.
    Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner LA, Hutchinson NI, Singer II, Donatelli SA, Weidner JR, Williams HR, Mumford RA, Lohmander LS.
    J Clin Invest; 1997 Jul 01; 100(1):93-106. PubMed ID: 9202061
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Role of metalloproteinases in human osteoarthritis.
    Woessner JF, Gunja-Smith Z.
    J Rheumatol Suppl; 1991 Feb 01; 27():99-101. PubMed ID: 1851233
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.